COMMUNIQUÉS West-GlobeNewswire
-
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
20/05/2024 - 14:01 -
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
20/05/2024 - 14:01 -
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
20/05/2024 - 14:05 -
ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
20/05/2024 - 14:10 -
LIXTE Biotechnology Holdings Provides Update on Recent Activities
20/05/2024 - 14:30 -
Nanox to Report First Quarter and Financial Results on May 28, 2024
20/05/2024 - 14:30 -
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
20/05/2024 - 14:30 -
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
20/05/2024 - 14:30 -
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
20/05/2024 - 14:45 -
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
20/05/2024 - 15:00 -
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
20/05/2024 - 15:00 -
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
20/05/2024 - 15:15 -
American Addiction Centers Names Greenhouse Treatment Center a Veterans Center of Excellence
20/05/2024 - 15:50 -
Grin Garners Recognition From MedTech Breakthrough With “Best New Orthodontics Technology Solution”
20/05/2024 - 16:00 -
U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”
20/05/2024 - 16:36 -
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
20/05/2024 - 12:00 -
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
20/05/2024 - 12:00 -
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
20/05/2024 - 12:30 -
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
20/05/2024 - 12:30
Pages